Topline Phase 1 Trial Results for Apogee’s APG777 in AD “Exceed Expectations”
Apogee Therapeutics, Inc.’s APG777 a novel, subcutaneous extended half-life monoclonal antibody targeting IL-13, exceeded expectations in a first-in-human Phase 1 healthy volunteer trial, the Company reports. APG777 is the first clinical-stage product candidate from the company’s strategic collaboration with Paragon Therapeutics, Inc. Pharmacokinetic (PK) data showed a half-life of approximately 75 days across doses tested […]